Tildrakizumab is a monoclonal antibody targeting interleukin-23 that has gained regulatory approval for moderate-to-severe plaque psoriasis in several jurisdictions. While phase III clinical trials have evaluated its short-term efficacy and safety, real-world evidence regarding its long-term retention is limited. We report real-world drug survival of tildrakizumab in the routine clinical setting.
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective study / T. Torres, S. Sood, O. Yilmaz, R.B. Vender, V.H. Prajapati, L. Puig, M. Megna, A.V. Marzano, P. Gisondi, J.M. Carrascosa, E. Dauden, M. Llamas-Velasco, A. Balato, B.G. Leal, F. Prignano, F. Bellinato, G. Silvi, E.V. Di Brizzi, L. Potestio, A. Sechi, C.G. Carrera, A. López-Ferrer, E. Del-Alcazar, A. Mufti, L.V. Maul, S. Piaserico, J. Maul, J. Yeung. - In: CLINICAL AND EXPERIMENTAL DERMATOLOGY. - ISSN 0307-6938. - (2025 Jul 29). [Epub ahead of print] [10.1093/ced/llaf342]
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective study
A.V. Marzano;
2025
Abstract
Tildrakizumab is a monoclonal antibody targeting interleukin-23 that has gained regulatory approval for moderate-to-severe plaque psoriasis in several jurisdictions. While phase III clinical trials have evaluated its short-term efficacy and safety, real-world evidence regarding its long-term retention is limited. We report real-world drug survival of tildrakizumab in the routine clinical setting.
| File | Dimensione | Formato | |
|---|---|---|---|
|
llaf342.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
596.42 kB
Formato
Adobe PDF
|
596.42 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
